|
Synonyms: DX-2930 | lanadelumab-flyo | Takhzyro® | X124-G01
lanadelumab is an approved drug (EMA & FDA (2018))
Compound class:
Antibody
Comment: Lanadelumab is a fully human monoclonal antibody targeting the serine peptidase kallikrein B1 (KLKB1, a.k.a. plasma kallikrein). It is generated in recombinant Chinese hamster ovary cells.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent US8816055 [5]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Lanadelumab was evaluated in Phase 3 clinical trial in patients with hereditary angioedema (HAE)- see NCT02586805. The EMA granted orphan drug designation in 2015, and the FDA (2017) has designated lanadelumab as a breakthrough therapy for prevention of HAE attacks. In 2018, the EMA and FDA granted lanadelumab (Takhzyro®) full approval as a prophylactic for the prevention of swelling attacks caused by types I and II HAE. It can be prescribed for patients 12 years and older. COVID-19: Elevated levels of bradykinin have been detected in COVID-19 patients, and it is proposed that this might underlie many of the highly debilitating symptoms of the infection [1-2,4]. By inhibiting the plasma kallikrein-bradykinin axis lanadelumab provides an existing therapeutic option with potential to reduce the multi-system effects of bradykinin. SARS-CoV-2 destruction of ACE2 could participate in the loss of regulation of bradykinin levels [3]. Icatibant also acts on this pathway (it antagonises bradykinin signalling via its receptor), and is being tested in COVID-19 patients. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Uncontrolled plasma kallikrein activity leads to excessive generation of bradykinin. Bradykinin is a vasodilator that is believed to be responsible for the localized swelling, inflammation and pain characteristic of HAE. Lanadelumab-induced inhibition of plasma kallikrein is proposed to reduce formation of bradykinin, to bring about an improvement in disease symptoms. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02586805 | Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE | Phase 3 Interventional | Shire | ||
| NCT04460105 | Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia | Phase 1 Interventional | Takeda | ||
| NCT04422509 | Lanadelumab for Treatment of COVID-19 Disease | Phase 1/Phase 2 Interventional | Radboud University | ||
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |
